LX 1020
Alternative Names: LX-1020Latest Information Update: 14 Sep 2021
At a glance
- Originator Weill Cornell Medicine
- Developer LEXEO Therapeutics; Weill Cornell Medicine
- Class Antidementias; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Alzheimer's disease